➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Colorcon
McKinsey
Moodys
Express Scripts

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Patent: 10,088,479

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,088,479
Title:Biomarker and uses thereof
Abstract: The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.
Inventor(s): Midwood; Kim Suzanne (Headington, GB), Venables; Patrick John (Headington, GB)
Assignee: OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB)
Application Number:15/109,775
Patent Claims:see list of patent claims

Details for Patent 10,088,479

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22 ⤷  Free Forever Trial OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22 ⤷  Free Forever Trial OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX Orphan search
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21 ⤷  Free Forever Trial OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX Orphan search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 003 2010-01-08 ⤷  Free Forever Trial OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX Orphan search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 002 2010-01-08 ⤷  Free Forever Trial OXFORD UNIVERSITY INNOVATION LIMITED (Oxford, GB) 2034-01-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Mallinckrodt
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.